Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy
The immune cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has received significant attention as a cancer therapeutic due to its ability to selectively trigger cancer cell apoptosis without causing toxicity in vivo. While TRAIL has demonstrated significant promise in preclin...
| Main Authors: | , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
American Chemical Society (ACS)
2021
|
| Online Access: | https://hdl.handle.net/1721.1/130132 |
| _version_ | 1826214687369330688 |
|---|---|
| author | Guimarães, Pedro P.G. Gaglione, Stephanie Sewastianik, Tomasz Carrasco, Ruben D. Langer, Robert S Mitchell, Michael J. |
| author2 | Massachusetts Institute of Technology. Department of Chemical Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Chemical Engineering Guimarães, Pedro P.G. Gaglione, Stephanie Sewastianik, Tomasz Carrasco, Ruben D. Langer, Robert S Mitchell, Michael J. |
| author_sort | Guimarães, Pedro P.G. |
| collection | MIT |
| description | The immune cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has received significant attention as a cancer therapeutic due to its ability to selectively trigger cancer cell apoptosis without causing toxicity in vivo. While TRAIL has demonstrated significant promise in preclinical studies in mice as a cancer therapeutic, challenges including poor circulation half-life, inefficient delivery to target sites, and TRAIL resistance have hindered clinical translation. Recent advances in drug delivery, materials science, and nanotechnology are now being exploited to develop next-generation nanoparticle platforms to overcome barriers to TRAIL therapeutic delivery. Here, we review the design and implementation of nanoparticles to enhance TRAIL-based cancer therapy. The platforms we discuss are diverse in their approaches to the delivery problem and provide valuable insight into guiding the design of future nanoparticle-based TRAIL cancer therapeutics to potentially enable future translation into the clinic. ©2018 American Chemical Society. |
| first_indexed | 2024-09-23T16:09:47Z |
| format | Article |
| id | mit-1721.1/130132 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T16:09:47Z |
| publishDate | 2021 |
| publisher | American Chemical Society (ACS) |
| record_format | dspace |
| spelling | mit-1721.1/1301322022-10-02T06:45:58Z Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy Guimarães, Pedro P.G. Gaglione, Stephanie Sewastianik, Tomasz Carrasco, Ruben D. Langer, Robert S Mitchell, Michael J. Massachusetts Institute of Technology. Department of Chemical Engineering Koch Institute for Integrative Cancer Research at MIT The immune cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has received significant attention as a cancer therapeutic due to its ability to selectively trigger cancer cell apoptosis without causing toxicity in vivo. While TRAIL has demonstrated significant promise in preclinical studies in mice as a cancer therapeutic, challenges including poor circulation half-life, inefficient delivery to target sites, and TRAIL resistance have hindered clinical translation. Recent advances in drug delivery, materials science, and nanotechnology are now being exploited to develop next-generation nanoparticle platforms to overcome barriers to TRAIL therapeutic delivery. Here, we review the design and implementation of nanoparticles to enhance TRAIL-based cancer therapy. The platforms we discuss are diverse in their approaches to the delivery problem and provide valuable insight into guiding the design of future nanoparticle-based TRAIL cancer therapeutics to potentially enable future translation into the clinic. ©2018 American Chemical Society. Cancer Center Support (core) Grant (P30-CA14051) Ruth L. Kirschstein National Research Service Award from the NIH (F32CA200351) Burroughs Wellcome Fund (No. 1015145) 2021-03-15T12:43:27Z 2021-03-15T12:43:27Z 2018-01 2017-08 2019-09-09T13:00:04Z Article http://purl.org/eprint/type/JournalArticle 1936-086X https://hdl.handle.net/1721.1/130132 Guimarães, Pedro P.G. et al., "Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy." ACS Nano 12, 2 (February 2018): 912–31 ©2018 Authors en https://dx.doi.org/10.1021/ACSNANO.7B05876 ACS Nano Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. application/pdf American Chemical Society (ACS) PMC |
| spellingShingle | Guimarães, Pedro P.G. Gaglione, Stephanie Sewastianik, Tomasz Carrasco, Ruben D. Langer, Robert S Mitchell, Michael J. Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy |
| title | Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy |
| title_full | Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy |
| title_fullStr | Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy |
| title_full_unstemmed | Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy |
| title_short | Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy |
| title_sort | nanoparticles for immune cytokine trail based cancer therapy |
| url | https://hdl.handle.net/1721.1/130132 |
| work_keys_str_mv | AT guimaraespedropg nanoparticlesforimmunecytokinetrailbasedcancertherapy AT gaglionestephanie nanoparticlesforimmunecytokinetrailbasedcancertherapy AT sewastianiktomasz nanoparticlesforimmunecytokinetrailbasedcancertherapy AT carrascorubend nanoparticlesforimmunecytokinetrailbasedcancertherapy AT langerroberts nanoparticlesforimmunecytokinetrailbasedcancertherapy AT mitchellmichaelj nanoparticlesforimmunecytokinetrailbasedcancertherapy |